Digital Health Technologies (DHTs) offer new opportunities to improve measurement strategies in CNS clinical trials. This white paper examines how digital endpoints and biomarkers – derived from sensors, software, and connected devices – can complement or enhance traditional clinical outcome assessments (COAs). Explore real-world use cases, including functional outcomes, symptom monitoring, and population stratification, and see how DHTs are paving the way for more sensitive, scalable, and patient-centric trials.